A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The primary purpose of this study is to determine the non-inferiority of overall survival FOLFIRI with or without Bevacizumab compared with Irinotecan (CPT-11) with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.
Epistemonikos ID: 1434195ea1e2aab7a3847a5b6c7d3fb1fb90b307
First added on: May 21, 2024